BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1030@pharmaconomics
DTSTAMP:20260707T034933Z
DTSTART;VALUE=DATE:20260115
DTEND;VALUE=DATE:20260116
SUMMARY:OCGN Phase 1 — OCU410
DESCRIPTION:Phase 1 trial results for OCU410 in geographic atrophy secondary to dry age-related macular degeneration are due Jan 15\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1372299/000110465926003900/tm263269d1_ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/1030
URL:https://www.pharmaconomics.com/e/1030
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:OCGN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR